Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

NCT00402727 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

813

Enrollment

INDUSTRY

Sponsor class

Conditions

Abscess
Wound Infection
Diabetic Foot
Ulcer

Interventions

DRUG: Moxifloxacin (Avelox, BAY12-8039)
DRUG: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid

Sponsor

Bayer